We welcome any and all commercial Next-Generation Sequencing players into our ecosystem. We believe that through out-licensing we can achieve an impact in this scattered market.

With strength in numbers we can achieve our mutual goals — enabling consistently accurate and fast diagnostics results for a fraction of the current cost.

We are actively looking for global level technology partnerships within liquid biopsy, infectious diseases (Covid19), NIPT, tropical diseases, antibiotic resistance – among others.